Skip to main content

Doug Farrell, David Block


Affymetrix has appointed Doug Farrell as its new vice president of investor relations. Farrell comes to Affymetrix from Aurora Biosciences, where he served as senior director of investor relations and corporate communications. Aurora was acquired by Vertex Pharmaceuticals in July.


David Block has been appointed executive vice president of Celera, and chief operating officer of Celera’s therapeutics business. Block comes to Celera from DuPont Pharmaceuticals, where he worked for 12 years, most recently serving as executive vice president for international operations.

At Celera, Block will oversee the development of its pharmaceutical business, coordinating the therapeutic program, and will oversee mergers and acquisitions, as well as directing alliances and licensing agreements with other companies.

Block replaces Peter Barrett, a co-founder of Celera who served as chief business officer and executive vice president. Barrett has accepted a position at Atlas Venture, a leading life sciences venture capital firm. Barrett will work with Jean-Francois Formela out of Atlas’ Boston office to lead investments in US life sciences companies.

Before founding Celera, Barrett moved PerkinElmer into life sciences, shepherding its acquisition of Applied Biosystems in 1993.

The Scan

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.